Efficacy and Safety of a New 24-day Oral Contraceptive Regimen of Norethindrone Acetate 1 mg/Ethinyl Estradiol 20 μg Given for 24 Days Compared to a 21-day Regimen

2005 ◽  
Vol 84 ◽  
pp. S169-S170
Author(s):  
H. Ellman ◽  
D.F. Archer
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety ◽  
Norethindrone Acetate

Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin® 24 Fe)

Contraception ◽  
2007 ◽  
Vol 75 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Steven T. Nakajima ◽  
David F. Archer ◽  
Herman Ellman
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety ◽  
Norethindrone Acetate

Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris

2001 ◽  
Vol 1 (3) ◽  
pp. 123-131 ◽  
Author(s):  
J. Michael Maloney ◽  
Deborah I. Arbit ◽  
Mary Flack ◽  
Constance McLaughlin-Miley ◽  
Cynthia Sevilla ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Acne Vulgaris ◽  
Dose Oral ◽  
Dose Oral Contraceptive ◽  
Norethindrone Acetate

The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol

Contraception ◽  
2010 ◽  
Vol 81 (1) ◽  
pp. 41-48 ◽  
Author(s):  
Robin Kroll ◽  
Kathleen Z. Reape ◽  
Marya Margolis
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive

Contraception ◽  
2014 ◽  
Vol 89 (4) ◽  
pp. 299-306 ◽  
Author(s):  
David J. Portman ◽  
Andrew M. Kaunitz ◽  
Brandon Howard ◽  
Herman Weiss ◽  
Jennifer Hsieh ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety ◽  
Combined Oral Contraceptive

Estradiol Valerate/Dienogest: A Novel Oral Contraceptive

2011 ◽  
Vol 45 (10) ◽  
pp. 1256-1261 ◽  
Author(s):  
Karen L Whalen ◽  
Renee Rose
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Data Extraction ◽  
Estradiol Valerate ◽  
Efficacy And Safety ◽  
Data Synthesis ◽  
Efficacy Trials ◽  
Study Selection ◽  
Pearl Index

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the new oral contraceptive estradiol valerate/dienogest. Data Sources: Searches of PubMed (1966-July 2011) and International Pharmaceutical Abstracts (1970-July 2011) were conducted using the key words estradiol valerate, dienogest, Natazia, and Olaira. Bibliographies of retrieved articles were reviewed to identify additional références. Study Selection and Data Extraction: All identified studies published in English and involving efficacy and safety of estradiol valerate/dienogest as an oral contraceptive were reviewed. Data Synthesis: Estradiol valerate/dienogest is a 4-phasic oral contraceptive approved for the prevention of pregnancy. The 4-phasic design allows for acceptable cycle control with this hormonal combination. In efficacy trials of estradiol valerate/dienogest in women aged 18–35 years, the Pearl Index ranged from 0.40 to 1.64, a range comparable to that of other combination oral contraceptives. The safety profile was also similar to that of other oral contraceptives, with headache, metrorrhagia, breast tenderness, nausea or vomiting, acne, and weight gain reported as the most common adverse effects. Menstrual bleeding patterns and cycle control with estradiol valerate/dienogest were comparable to those of a monophasic oral contraceptive containing ethinyl estradiol/levonorgestrel. Estradiol valerate/dienogest differs from other oral contraceptives in that il necessitates more stringent dosing guidelines for maximum contraceptive efficacy. New starts should be on the first day of menses only, and a back-up method of contraception is required for the first 9 days, as compared to 7 days with other oral contraceptives. Back-up contraception is usually required for any pill taken more than 12 hours later than scheduled. Conclusions: Estradiol valerate/dienogest is an effective oral contraceptive. Because it has more stringent start times and requires a longer duration of back-up contraception and stricter adherence, estradiol valerate/dienogest should be reserved for patients who are intolerant of other combination oral contraceptives.

Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate

Contraception ◽  
2009 ◽  
Vol 79 (3) ◽  
pp. 182-188 ◽  
Author(s):  
Radhika D. Rible ◽  
DeShawn Taylor ◽  
Melissa L. Wilson ◽  
Frank Z. Stanczyk ◽  
Daniel R. Mishell
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Follicular Development ◽  
Free Interval ◽  
Norethindrone Acetate

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)

1999 ◽  
Vol 181 (5) ◽  
pp. S39-S44 ◽  
Author(s):  
David F. Archer ◽  
Rodolphe Maheux ◽  
Anthony DelConte ◽  
Francis B. O’Brien
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document